Zenas BioPharma, Inc.

NASDAQ:ZBIO

Biotechnology

Healthcare
$26.42 +3.46%

+$0.64 today

Market cap
$1.79B
Beta
-0.69
P/E (TTM)
-2.5
EPS (TTM)
-$7.64
52W Low $8.91High $44.60

Volume 0.48M

Average 0.71M

ZBIO Account Payables

Amounts the company owes suppliers for goods and services received.

Zenas BioPharma, Inc.NASDAQ: ZBIO

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables falls 55.3% from a year ago

Account payables stood at $8.94M at the end of Q1 FY2026, down 55.3% from a year earlier and up 25.8% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.

Context

  • Account payables amounted to 1.2% of total assets at the end of Q1 FY2026, down 4.8 pp from a year earlier.
  • Account payables increased in 1 of the last 3 fiscal years.

What to watch

Whether account payables keeps falling in the next quarterly balance sheet after a -55.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.94M+25.8% QoQ
Last fiscal yearDec 2025
$7.11M-58.5% YoY
Year agoMar 2025
$20.02M-55.3% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-55.3%——
1 year-58.5%——
3-year CAGR+6.9%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
7.11M USD
Year-over-year change
-58.5%
3-year CAGR
+6.9%

Account Payables vs competitors

How ZBIO compares with its peers on the latest reported figures

  • ZBIO's Mar 2026 account payables of $8.94M is the 3rd highest of the 8 companies compared; the peer median is $7.17M.
  • Its year-over-year change of -55.3% is the 5th highest of 7, against a peer median of +13.3%.
  • Account payables amounts to 1.2% of total assets for ZBIO, versus a peer median of 2.6%.
ZBIO Competitors Peer median
Account Payables for ZBIO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANNXAnnexon, Inc.Mar 2026$17.53M +68.0%+26.3%6.7%
ACRSAclaris Therapeutics, Inc.Mar 2026$14.73M +131.8%+8.3%7.4%
ZBIOZenas BioPharma, Inc.Mar 2026$8.94M -55.3%+6.9%1.2%
TRAXFirst Tracks Biotherapeutics IncMar 2026$7.5M ——2.6%
TLSATiziana Life Sciences LtdDec 2025$7.17M +28.5%+13.1%62.4%
IMVTImmunovant, Inc.Sep 2026$6.79M -1.9%+77.3%0.9%
UPBUpstream Bio, Inc.Mar 2026$1.71M -63.8%+56.4%0.5%
QTTBQ32 Bio Inc.Mar 2026$653K -75.9%-15.1%1.0%
Peer median (excluding ZBIO) $7.17M+13.3%+19.7%2.6%

Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents67.21M56.86M319.74M110.64M
Short-term Investments0031.02M232.55M
Net Receivables0000
Inventory0000
Other Current Assets1.24M2.95M5.16M7.98M
Total Current Assets68.44M59.8M355.92M351.17M
Property, Plant & Equipment (Net)1.8M1.01M1.19M1.39M
Goodwill0000
Intangible Assets0000
Long-term Investments00017.27M
Tax Assets0000
Other Non-current Assets4.33M7.36M12.86M13.81M
Total Non-current Assets6.14M8.38M14.05M32.47M
Total Assets74.58M68.18M369.97M383.64M
Account Payables5.82M5.4M17.14M7.11M
Short-term Debt0001.12M
Tax Payables0301K211K0
Deferred Revenue0000
Other Current Liabilities4.33M5.12M8.31M41.23M
Total Current Liabilities25.97M23.26M57.29M62.65M
Long-term Debt020.3M078.64M
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities240.09M250.09M00
Total Non-current Liabilities240.9M270.64M218K78.85M
Total Liabilities266.87M293.9M57.51M141.5M
Common Stock004K5K
Retained Earnings(193.28M)(230.4M)(387.39M)(765.13M)
Accumulated OCI(41K)37K194K(64K)
Other Stockholders Equity0000
Minority Interest0000
Total Equity(192.29M)(225.72M)312.46M242.14M
Total Debt1.53M21.11M1M79.96M
Net Debt(65.68M)(35.74M)(318.74M)(30.68M)

Zenas BioPharma, Inc.

NASDAQ:ZBIO

Intrinsic Alpha fair value

Locked

Current Price

$26.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.